Dr. Reddy's Laboratories Limited (NYSE:RDY) Stake Lifted by Vident Advisory LLC

Vident Advisory LLC raised its holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 535.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 151,331 shares of the company's stock after acquiring an additional 127,518 shares during the period. Vident Advisory LLC's holdings in Dr. Reddy's Laboratories were worth $2,390,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of RDY. Robeco Institutional Asset Management B.V. grew its stake in shares of Dr. Reddy's Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock valued at $180,620,000 after buying an additional 9,373,412 shares during the period. Royal Bank of Canada boosted its position in Dr. Reddy's Laboratories by 403.1% during the 4th quarter. Royal Bank of Canada now owns 10,037,246 shares of the company's stock worth $158,489,000 after purchasing an additional 8,042,163 shares during the period. Renaissance Technologies LLC boosted its holdings in Dr. Reddy's Laboratories by 382.9% in the fourth quarter. Renaissance Technologies LLC now owns 9,418,428 shares of the company's stock valued at $148,717,000 after purchasing an additional 7,467,979 shares during the last quarter. Aikya Investment Management Ltd grew its stake in Dr. Reddy's Laboratories by 416.1% during the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock valued at $88,590,000 after purchasing an additional 4,523,303 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Dr. Reddy's Laboratories by 405.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 5,361,013 shares of the company's stock valued at $84,643,000 after purchasing an additional 4,301,212 shares in the last quarter. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy's Laboratories Stock Performance

RDY traded up $0.35 on Tuesday, hitting $14.73. 450,549 shares of the company's stock were exchanged, compared to its average volume of 2,046,498. The stock has a fifty day moving average of $13.60 and a two-hundred day moving average of $14.00. Dr. Reddy's Laboratories Limited has a twelve month low of $12.26 and a twelve month high of $16.89. The firm has a market cap of $12.29 billion, a PE ratio of 23.45 and a beta of 0.33. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.20 by $0.02. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. The company had revenue of $996.17 million for the quarter, compared to analyst estimates of $83.70 billion. On average, research analysts anticipate that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.